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Abstract
Background: Influenza vaccination is recommended for all US residents aged 
≥6 months. Vaccine effectiveness (VE) varies by age, circulating influenza strains, and 
the presence of high-risk medical conditions. We examined site-specific VE in the US 
Influenza VE Network, which evaluates annual influenza VE at ambulatory clinics in 
geographically diverse sites.
Methods: Analyses were conducted on 27 180 outpatients ≥6 months old present-
ing with an acute respiratory infection (ARI) with cough of ≤7-day duration during 
the 2011-2016 influenza seasons. A test-negative design was used with vaccination 
status defined as receipt of ≥1 dose of any influenza vaccine according to medical 
records, registries, and/or self-report. Influenza infection was determined by reverse-
transcription polymerase chain reaction. VE estimates were calculated using odds 
ratios from multivariable logistic regression models adjusted for age, sex, race/eth-
nicity, time from illness onset to enrollment, high-risk conditions, calendar time, and 
vaccination status-site interaction.
Results: For all sites combined, VE was statistically significant every season against 
all influenza and against the predominant circulating strains (VE = 19%-50%) Few 
differences among four sites in the US Flu VE Network were evident in five seasons. 
However, in 2015-16, overall VE in one site was 24% (95% CI = −4%-44%), while VE in 
two other sites was significantly higher (61%, 95% CI = 49%-71%; P = .002, and 53%, 
95% CI = 33,67; P = .034).
Conclusion: With few exceptions, site-specific VE estimates aligned with each other 
and overall VE estimates. Observed VE may reflect inherent differences in commu-
nity characteristics of the sites and highlights the importance of diverse settings for 
studying influenza vaccine effectiveness.
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1  | INTRODUC TION
Each year, infection with influenza causes an estimated 9.3 million to 
45 million illnesses in the United States1 and an associated average 
cost of $11.2 billion.2 Annual vaccination is the most effective strat-
egy for preventing influenza and reducing these burdens, as it has 
been shown to reduce the risk of influenza illness among the general 
population by 40%-60% when the vaccine is well-matched to the 
circulating viruses.3
The effectiveness of seasonal influenza vaccines is evaluated 
through the Centers for Disease Control and Prevention (CDC) US 
Influenza Vaccine Effectiveness Network, (US Flu VE Network or 
Network) which was established in the 2003-2004 influenza sea-
son.4 The current Network conducts observational studies across 
five sites in the United States to evaluate medically attended, labo-
ratory-confirmed influenza and estimate vaccine effectiveness (VE) 
using a test-negative design.5 Enrollees are outpatients seeking care 
for acute respiratory illness (ARI) who are tested for influenza using 
CDC's reverse-transcription polymerase chain reaction (RT-PCR) 
assay. VE is estimated by comparing the odds of vaccination among 
influenza-positive and influenza-negative outpatients who present 
with ARI.
Recent estimates of influenza VE have demonstrated varying VE 
across influenza subtypes.6 For example, vaccines tend to be more 
effective for preventing infection with influenza B and influenza A/
H1N1 viruses compared to influenza A/H3N2.3 In a meta-analysis of 
VE studies during the 2004-2005 to 2014-2015 influenza seasons, 
pooled VE estimates were as follows: 33% (95% confidence inter-
val [CI] = 26%–39%) for A/H3N2 viruses, 61% (95% CI = 57%–65%) 
for A/H1N1 viruses, and 54% (95% CI = 46%–61%) for influenza B 
viruses.6
Vaccine effectiveness estimates against influenza may differ 
geographically due to characteristics of the study population, type 
of vaccine purchased by large healthcare organizations or pharma-
cies, vaccination coverage levels, and different circulating influenza 
strains. Studies from other countries indicate VE differences by 
strain/lineage, vaccine to circulating strain matching, age and birth 
cohort, and vaccination history.7-9 In an agent-based cost-effective-
ness analysis using synthetic populations, DePasse et al showed dif-
ferent epidemiologic curves and different numbers of averted cases 
of influenza across five US counties that differed by demographic 
characteristics such as size, density, and age distributions of their 
populations.10
The US Flu VE Network consists of geographically and demo-
graphically distinct sites that contribute to annual estimations of 
influenza VE. It is unknown whether influenza VE differs across the 
sites that comprise the Network. In this study, we estimate site-spe-
cific influenza VE among outpatients who presented with ARI during 
the 2011-2016 influenza seasons at four of the five US Flu VE 
Network sites.
2  | METHODS
Data were collected using a standardized protocol, as part of the CDC's 
US Flu VE Network study, for which detailed methods have been de-
scribed.11-16 IRB approval for the Flu VE Network protocol for all sites 
was granted. The screening criteria for an ARI were intentionally broad 
in order to maximize the pool of potential participants and included 
symptoms such as sore throat, fever/feverishness, congestion, wheez-
ing, increased nasal secretions, body aches, and cough. Eligible partici-
pants were outpatients ≥6 months old seeking care for an ARI of less 
than 7-day duration with a cough. Patients who had received antivi-
ral medication in the 7 days prior to enrollment, were younger than 
6 months old, had enrolled in the study during the previous 14 days, 
or had received influenza vaccine within 14 days of enrollment were 
not eligible for enrollment or data analysis. Consented participants 
provided data on demographics, symptoms and other measures of 
current health and well-being, general health status, and self-report of 
influenza vaccination that were collected during patient enrollment in-
terviews. High-risk conditions identified by International Classification 
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of Diseases code Clinical Modification (versions 9 and 10 [ICD-9/10]) 
assigned to a medical encounter during the year prior to enrollment 
were used to determine the presence of underlying health conditions 
associated with an increased risk of severe influenza.16,17 ICD-9/10 
codes were derived from electronic medical records (EMR).
2.1 | Sites
The US Flu VE Network was designed to include geographically di-
verse settings. The four sites included in this analysis were as follows: 
a large health maintenance organization located in and around Seattle, 
Washington, with a significant minority population of Asian enrollees; 
one site in a large university-affiliated health system located in north 
central Texas with a significant minority population of Latino enroll-
ees; one site that combined outpatient clinics from a university health 
system and an inner-city health system located in Michigan with a sig-
nificant minority population of black enrollees; and one site in a single 
large health system located in a county in Pennsylvania with one of the 
highest percentages in the USA of residents >65 years.
2.2 | Influenza vaccine
The influenza vaccine strains used each year are shown in Table 
S1. For all five seasons, the A/H1N1 vaccine strain was the A/
California/7/2009, while the A/H3N2 strain changed in all years 
but 2013-2014 and 2014-2015. The trivalent influenza vaccine 
contained a B/Victoria virus (B/Brisbane) in 2011-2012 and B/
Yamagata virus for the next 4 seasons (B/Wisconsin in 2012-2013, 
B/Massachusetts in 2013-2014 through 2014-2015, and B/Phuket 
in 2015-2016).17-21 The quadrivalent vaccine was introduced in the 
2013-2014 season and added a B/Victoria (B/Brisbane) virus each 
subsequent year.
Each season, vaccination status was defined as receipt of at 
least one dose of any seasonal influenza vaccine (including for chil-
dren < 9 years old), according to EMR, immunization registries, and/
or plausible self/parental-report (with estimated date and plausible 
location of vaccination). All sites used the same questionnaire to 
query enrollees about vaccination at enrollment. Vaccination status 
was confirmed using data requests from the EMR and state immuni-
zation registries (electronic records), followed by requests to health 
insurance plans and providers such as physicians' offices, work and 
community sites, and pharmacies. For the remaining unconfirmed 
vaccinations, plausible self-report was based on additional informa-
tion provided by the enrollee that had to include a location and ap-
proximate date.
2.3 | Laboratory methods
Nasal and throat swabs were collected from participants ≥2 years 
old, and nasal swabs only were collected from children <2 years old. 
These specimens were tested for influenza using RT-PCR with CDC-
provided primers and probes and were tested for A/subtype and B/
lineage. Patients who tested positive for influenza were cases, and 
patients who tested negative for influenza were controls.
2.4 | Statistical analysis
The influenza circulation period was calculated for each site in the 
Network. It was defined as the dates between the first and last influ-
enza-positive enrollment during each season. Participants enrolled 
outside the influenza circulation periods were excluded from analy-
ses. The enrollment period details for the Network sites are shown 
in Table S2.
Baseline characteristics were compared across sites using chi-
square tests for categorical variables, and t tests or Wilcoxon rank-
sum statistics for continuous variables.
A test-negative design was used to estimate VE by comparing the 
odds of vaccination among RT-PCR confirmed influenza cases to the 
odds of vaccination among controls. Using odds ratios obtained from 
multivariable logistic regression models, VE estimates were calcu-
lated as VE = 100% × (1 − OR). A series of logistic regression models 
was conducted with RT-PCR confirmed influenza A and influenza B, 
and the predominant circulating virus for each season as the depen-
dent variable and vaccination status as the independent variable. 
The primary analyses determined VE for all influenza; subgroup 
analyses determined VE for influenza A\H1N1, influenza A\H3N2, 
influenza B Yamagata, and influenza B Victoria. The logistic regres-
sion models were adjusted a priori for age group (6 months-4 years, 
5-17 years, 18-49 years, 50-64 years, ≥65 years), sex, race/ethnicity 
(non-Hispanic white, non-Hispanic black, non-Hispanic other race, 
Hispanic any race), time from illness onset to enrollment (0-2, 3-4, 
5-7 days), presence of any high-risk condition as determined by ICD-
9/10 codes, and calendar time (illness onset date in bi-weekly inter-
vals). Inclusion of these adjustment variables is comparable to those 
used by the US Flu VE Network for its VE estimations.13
Site-specific differences in VE were estimated by four separate 
multivariable logistic regression models. For model 1, each site VE 
was independently estimated adjusting for age, sex, race/ethnicity, 
any high-risk condition, interval from onset to enrollment, and calen-
dar time. For model 2, overall VE combining all sites was estimated 
adjusting for the same variables used in model 1. For model 3, overall 
VE combining all sites was estimated as above, with a site variable 
added to adjust for possible confounding by study site. The site ref-
erence group was the Michigan site. Model 4 added site and vacci-
nation status interaction to the variables in model 3. The vaccination 
status (two levels) and the clinical site (four levels) were represented 
in model 4 as categorical variables. The vaccination status by site 
interaction had four levels with three degrees of freedom and was 
declared as a classification variable in the model, with one being the 
reference category.
In addition to individual season estimates, data across seasons in 
which the vaccine viruses were identical to each other and matched 
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the predominant viruses that circulated in the community, and for 
which there were sufficient numbers of cases to permit analysis, 
were combined for regression modeling with the site interaction 
term using model 4. Those seasons were 2013-14 and 2015-16 for 
A/H1N1 and 2013-14 and 2014-2015 for B/Yamagata. In seasons or 
combined seasons with statistically significant interactions, model 
4 was used to examine the significance of vaccination status by site 
interaction. When there was a significant interaction indicated, then 
the vaccine effect of each site was compared with the vaccine ef-
fect of the reference site (Michigan). The probability values for vac-
cination status, clinical site, and the interaction were derived using 
Wald-chi-square test.
Further, the statistical heterogeneity of estimates across sites 
was assessed using I2 statistic calculated from a random effects me-
ta-analysis.22 Estimates of I2 > 50% were considered to be highly 
heterogeneous. Data were analyzed using SAS version 9.4 (SAS 
Institute). Statistical significance was set at P < .05.
3  | RESULTS
There were 27 180 outpatients seeking care for ARI who were enrolled 
at the 4 US Flu VE Network sites within the annual circulation periods 
from January 12, 2012, to April 14, 2016, (Figure 1) after excluding 
F I G U R E  1   Enrollment Flow chart
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555 influenza-negative patients (2%) who were enrolled outside those 
periods and the 292 (1%) who were vaccinated ≤14 days before ill-
ness onset. Twenty-one percent (n = 2083) were influenza-positive, 
and 79% (n = 21 362) were influenza-negative. Of the influenza cases, 
48% (n = 2770) were infected with A/H3N2, 26% (n = 1493) with A/
H1N1 pdm09, 16.7% (n = 971) with B/Yamagata, and 7.3% (n = 426) 
with B/Victoria viruses. In addition, 92 influenza A viruses could not be 
subtyped, 41 influenza B viruses had no lineage identified due to high 
CT values, seven patients had influenza A/B co-infections, and 18 pa-
tients' influenza results could not be confirmed. All individuals were in-
cluded in the overall analyses, but those who were not subtyped were 
excluded from the subtype analyses.
Table S1 shows the circulating and vaccine viruses for each sea-
son. The predominant circulating strain varied from season to season 
but was identical across all Network sites for each season.
3.1 | Enrollee characteristics
There were significant differences among sites (P < .001) across 
each demographic variable measured (Table 1). For example, the 
Washington site enrolled the lowest proportion of children (26%) 
and the highest proportion of senior adults (≥65 years; 17%), 
whereas the Michigan site enrolled the highest proportion of 
TA B L E  1   Demographic characteristics, symptoms, and influenza status of enrollees in four US Flu VE Network sites over five influenza 
seasons, 2011-2016
Characteristic
Michigan (N = 5969)
Pennsylvania 
(N = 6379) Texas (N = 6287)
Washington 
(N = 8545)
P valueN (%) N (%) N (%) N (%)
Age group
6 mo-4 y 1209 (20.2) 916 (14.4) 1008 (16.0) 978 (11.5) <.001
5-17 y 1634 (27.4) 1149 (18.0) 1726 (27.4) 1269 (14.9)
18-49 y 1663 (27.9) 2626 (41.2) 2103 (33.5) 3191 (37.3)
50-64 y 969 (16.2) 1141 (17.9) 873 (13.9) 1686 (19.7)
≥65 y 494 (8.3) 547 (8.6) 577 (9.2) 1421 (16.6)
Sex
Male 2697 (45.2) 2630 (41.2) 2544 (40.5) 3788 (44.3) <.001
Female 3272 (54.8) 3749 (58.8) 3743 (59.5) 4757 (55.7)
Race/Ethnicity
White, non-Hispanic 3580 (60.2) 4973 (78.3) 4080 (64.9) 6163 (72.3) <.001
Black, non-Hispanic 1223 (20.6) 875 (13.8) 392 (6.2) 321 (3.8)
Other race, 
non-Hispanic
823 (13.8) 368 (5.8) 290 (4.6) 1379 (16.2)
Hispanic, any race 321 (5.4) 132 (2.1) 1520 (24.2) 656 (7.7)
Self-rated general health status
Excellent/Very good 4345 (73.0) 4367 (68.6) 4461 (71.0) 5874 (68.8) <.001
Good 1246 (20.9) 1614 (25.3) 1402 (22.3) 2051 (24.0)
Fair/Poor 362 (6.1) 389 (6.1) 421 (6.7) 612 (7.2)
Any high-risk condition 1966 (32.9) 2037 (31.9) 2133 (33.9) 3255 (38.1) <.001
Presenting symptoms
Fever 3373 (65.6) 3712 (58.2) 3353 (64.2) 4432 (63.8) <.001
Fatigue 2100 (82.2) 4709 (73.8) 1737 (81.3) 2165 (91.6) <.001
Sore Throat 3475 (67.6) 4265 (66.9) 3929 (76.5) 5174 (74.5) <.001
Influenza status
RT-PCR negative 4497 (75.3) 4800 (75.2) 5038 (80.1) 7027 (82.2) <.001
RT-PCR positive 1472 (24.7) 1579 (25.8) 1249 (19.9) 1518 (17.8)
Interval from onset to enrollment
0-2 d 2019 (33.8) 2140 (33.6) 2547 (40.7) 1814 (21.2) <.001
3-4 d 2398 (40.2) 2764 (43.4) 2312 (37.0) 3280 (38.4)
5-7 d 1552 (26.0) 1463 (23.0) 1395 (22.3) 3451 (40.4)
Vaccinated 2655 (44.5) 2766 (43.4) 2436 (38.8) 4606 (53.9) <.001
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children (48%) and the lowest proportion of senior adults (8%), 
and the Pennsylvania site enrolled the largest proportion of work-
ing age adults (59%). Commensurate with this age distribution, 
the Washington site enrolled the highest proportion of partici-
pants with presence of a high-risk condition (38%) and the high-
est vaccination rate (54%). More females than males enrolled in 
the study, and the racial/ethnic distribution of enrollees differed 
across sites, reflecting the racial/ethnic distributions of their re-
spective geographical regions (P < .001). Michigan enrolled the 
highest proportion of non-Hispanic black participants (21%), 
Washington enrolled the highest proportion of non-Hispanics 
from other racial groups (16%), and Texas enrolled the highest 
proportion of Hispanic participants (24%). In the Pennsylvania 
and Michigan sites, approximately one-quarter of enrollees were 
influenza cases compared with less than one-fifth in Texas and 
Washington. Over 40% of participants were enrolled within 
2 days of illness onset in Texas, between 3-4 days in Michigan and 
Pittsburgh and 5-7 days in Washington. Table S3 shows the vari-
ous types of influenza vaccines used by the sites over the 5 years 
of the study that likely reflected availability in the market and 
purchasing decisions by the sites.
Table 2 shows influenza vaccination rates among cases and 
controls for the five seasons combined for each site. In all cases, 
overall or by vaccine subtype, the proportion of vaccinated controls 
exceeded the proportion of vaccinated cases, indicating some pro-
tection by the vaccine. Table 3 shows the number and percentage 
of cases caused by each virus strain by site, each season. There are 
noticeable differences among the sites most seasons. For example, 
in 2013-14 in Michigan and Pennsylvania, 89%-93% of cases were 
A/H1N1, whereas in Texas and Washington, 77%-80% of cases were 
A/H1N1 with more of the remainder being B/Yamagata in these 
sites than in the former sites. In 2015-2016, the differences were 
more marked with Michigan and Pennsylvania A/H1N1 cases com-
prising 69%-70% of the total compared with 27%-30% in Texas and 
Washington.
Table 4 shows VE estimates for all enrollees combined for all in-
fluenza types and by the predominant circulating strains for each 
season. For all sites combined, VE was statistically significant every 
season against all influenza and against the predominant circulating 
strains (Model 2). Statistically significant VE was observed in at least 
one site during each of the study years. Each site had at least one 
year in which the vaccine was ineffective against the predominant 
strain.
When site was added to the model (Model 3), VE estimates were 
similar to the model without site included (Table 4, column 7), indi-
cating that site was not a confounder. To test for effect modification 
in the site differences, an interaction term was added to the model. 
Among the five seasons tested, the interaction term was significant 
only in 2015-2016 (P for the interaction term = .007). Individual 
comparisons of VE estimates between the sites revealed that the 
Washington and Texas sites had significantly higher overall VE (61%; 
P = .002 and 53%; P = .034, respectively) than the reference site, that 
is, the site with the lowest VE for that season, Michigan (VE = 24%).
Two analyses combined data from seasons in which the vaccine 
viruses were identical, the predominant A and B viruses that circu-
lated in the community were identical, and there were sufficient 
numbers of cases to permit analysis. Those seasons were 2013-
14 and 2015-16 for A/H1N1 and 2013-14 and 2014-2015 for B/
Yamagata. For A/H1N1, VE was 42% (95% CI = 28, 53; P for inter-
action = .025). Although all sites had significant VE against A/H1N1, 
individual comparisons of VE estimates between the sites revealed 
that the Washington site had significantly higher VE (65%) than the 
site with the lowest VE, Michigan (38%; P = .013). For B/Yamagata, 
VE was 42% (95% CI = −8, 72; P for interaction = 0.511). VE point 
estimates and confidence intervals for all seasons combined, for 
A/H1N1 for 2013 = 2014 and 2015-2016, and for all influenza for 
2015-2016, are shown in Figure 2.
In meta-analysis testing for heterogeneity across the four clini-
cal sites, three comparisons were made. Results are shown in Table 
S4. Consistent with the results reported in Table 4 for 2011-2016 
overall VE, no heterogeneity of VE was observed (chi-square = 5.95, 
P = .114, I2 = 49.6%). By contrast, the subgroup analysis of two 
seasons (2013-14 and 2015-16) with predominant A/H1N1 strain 
and overall analysis for one season 2015-2016 revealed that there 
is significant variation present among the clinical sites in VE with 
high heterogeneity (chi-square = 8.0, P = .046, I2 = 62.5% for com-
bined 2013-2014 and 2015-2016 A/H1N1 and chi-square = 11.91, 
P = .008, I2 = 74.8% for 2015-2015 overall VE). This heterogene-
ity was thought to have occurred because of the Washington site's 
differences in demographic characteristics and vaccination status. 
A sensitivity analysis was performed excluding the Washington site. 
The results revealed no heterogeneity for the combined 2013-2014 
and 2015-2016 seasons' A/H1N1 analysis (chi-square = 0.3, P = .861, 
I2 = 0%). For the 2015-2016 season overall VE, the heterogeneity 
declined to I2 = 51.7%, suggesting that the Washington site might be 
driving the observed differences.
TA B L E  2   Influenza vaccination of influenza controls, cases, and cases by strain/lineage in 4 US Flu VE Network sites, overall, and by 




Total cases (% 
vaccinated)
A/H1N1 cases (% 
vaccinated)






Michigan 2128 (47) 537 (36) 115 (36) 290 (38) 80 (27) 26 (46)
Pennsylvania 2208 (46) 558 (35) 156 (28) 305 (40) 56 (37) 24 (35)
Texas 2080 (41) 356 (28) 62 (25) 180 (34) 69 (26) 35 (21)
Washington 3964 (56) 642 (42) 115 (32) 370 (52) 89 (35) 44 (33)
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4  | DISCUSSION
During the 2011-2016 influenza seasons, the influenza vaccine 
provided moderate protection against influenza illness for which 
the patient sought outpatient care, as reported by the CDC's 
Influenza VE Network: 47% in 2011-2012; 49% in 2012-2013; 
54% in 2013-2014; 19% in 2014-2015; and 48% in 2015-2016.11-
14,16 In two seasons, influenza A/H1N1 predominated, and in 
three seasons, A/H3N2 predominated. The vaccine was effec-
tive across all four of the Network sites in two seasons (2012-
2013 and 2013-2014). In the other three seasons, the vaccine was 
effective against all influenza in three sites in 2011-2012 and in 
2015-2016, and two of the sites in 2014-2015. When site was 
included as an interaction term in regression models, VE against 
all influenza varied by site in only one season (2015-2016) and VE 
against A/H1N1 varied by site when the 2013-2014 and 2015-
2016 seasons were combined. These differences are not likely 
due to methodological differences, as a standard protocol was 
used across all sites, but may be attributed to differences in these 
geographically dispersed sites.
Geographical differences in the epidemiology of seasonal in-









N (%) All sites
2011-2012
A/H1N1 4 (2.0) 5 (9.4) 41 (83.7) 55 (24.6) 105
A/H3N2 182 (90.1) 45 (84.9) 5 (10.0) 72 (32.1) 304
B Victoria 1 (0.5) 0 (0) 0 (0) 61 (27.2) 62
B Yamagata 13 (6.4) 2 (3.8) 2 (4.1) 34 (15.2) 51
A/B 2 (1.0) 1 (1.9) 1 (2.0) 2 (0.9) 6
Total 202 53 49 224 528
2012-2013
A/H1N1 14 (2.6) 8 (2.1) 12 (2.7) 16 (7.1) 50
A/H3N2 261 (48.2) 270 (71.4) 227 (51.0) 178 (79.5) 936
B Victoria 20 (3.7) 28 (7.4) 44 (9.9) 6 (2.7) 98
B Yamagata 238 (44.0) 49 (13.0) 158 (35.5) 5 (2.2) 450
A/B 8 (1.5) 23 (6.1) 4 (0.9) 19 (8.5) 54
Total 541 378 445 224 1588
2013-2014
A/H1N1 129 (89.6) 288 (92.9) 144 (77.4) 196 (79.7) 757
A/H3N2 8 (5.5) 8 (2.6) 7 (3.8) 7 (2.9) 30
B Victoria 1 (0.7) 1 (0.3) 10 (5.4) 3 (1.2) 15
B Yamagata 4 (2.8) 8 (2.6) 17 (9.1) 23 (9.3) 52
A/B 2 (1.4) 5 (1.6) 8 (4.3) 17 (6.9) 32
Total 144 310 186 246 886
2014-2015
A/H1N1 1 (0.3) 0 (0) 0 (0) 3 (0.6) 4
A/H3N2 318 (92.7) 434 (90.6) 284 (74.5) 424 (82.3) 1460
B Victoria 1 (0.3) 7 (1.5) 25 (6.6) 13 (2.5) 46
B Yamagata 17 (5.0) 33 (6.9) 61 (16.0) 68 (13.2) 179
A/B 6 (1.7) 5 (1.0) 11 (2.9) 7 (1.4) 29
Total 343 479 381 515 1718
2015-2016
A/H1N1 177 (69.1) 258 (69.7) 53 (26.9) 98 (30.0) 586
A/H3N2 11 (4.3) 9 (2.4) 18 (9.1) 38 (11.6) 76
B Victoria 33 (12.9) 32 (8.6) 91 (46.2) 50 (15.3) 206
B Yamagata 22 (8.6) 60 (16.2) 31 (15.7) 128 (39.1) 241
A/B 13 (4.9) 11 (3.0) 4 (2.0) 13 (4.0) 41
Total 256 370 197 327 1150
TA B L E  3   Virus subtypes by season 
and site
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TA B L E  4   Adjusted vaccine effectiveness against medically attended influenza in 4 US Flu VE Network sites by season (2011-2016) and 
predominant virus subtype
Season
MODEL 1a  MODEL 2a  MODEL 3b 
MODEL 4c 
P value for 
interactione 
Adjustedd  VE, % (95% CI)
Overall
Overall with site 
addedMichigan Pennsylvania Texas Washington
2011-2012
Overall 46 (23, 62) 38 (−14, 66) 71 (37, 86) 55 (37, 68) 52 (40, 61) 53 (41, 62) .434
A/H3N2 42 (13, 60) 32 (−29, 65) 66 (−333, 97)f  44 (5, 62) 42 (24, 55) 40 (21, 54) .854
B/Victoria —g  —g  —g  62 (29, 80) 56 (20, 75) —g  —g 
B/Yamagata 87 (−4, 98) —g  —g  49 (−7, 76) 61 (26, 80) 65 (33, 82) —g 
2012-2013
Overall 52 (39, 62) 36 (17, 51) 56 (43, 66) 51 (31, 65) 50 (43, 56) 49 (42, 55) .136
A/H3N2 46 (27, 61) 36 (13, 53) 50 (31, 64) 37 (9, 57) 42 (32, 50) 43 (33, 51) .491
B/Yamagata 65 (50, 75) 13 (−71, 55) 58 (38, 72) —g  63 (54, 71) 59 (48, 67) —
2013-2014
Overall 58 (34, 73) 38 (14, 55) 45 (19, 63) 59 (44, 70) 51 (42, 59) 51 (41, 59) .215
A/H1N1 63 (40, 78) 41 (18, 58) 32 (−8, 57) 63 (48, 74) 53 (43, 61) 52 (42, 61) .088
B/Yamagata —g  —g  75 (8, 93) 34 (−56, 72) 47 (3, 71) 51 (9, 74) .911
2014-2015
Overall 15 (−10, 35) 36 (17, 50) 5 (−23, 26) 19 (0, 35) 19 (9, 28) 20 (10, 29) .124
A/H3N2 17 (−9, 37) 33 (17, 49) -6 (−44, 23) 11 (−13, 29) 14 (2, 25) 16 (5, 27) .115
B/Yamagata −18 (−232, 58) 48 (−11, 76) 29 (−26, 60) 58 (28, 76) 42 (19, 58) 39 (16, 56) .298
2015-2016h 
Overall 24 (−4, 44) 40 (22, 54) 53 (33, 67) 61 (49, 71) 44 (35, 51)  .007
Vaccination status × Site (ref., = Michigan) Pennsylvania 14 (−26, 42) .438
     Texas 39 (4, 61) .034
     Washington 47 (20, 64) .002
A/H1N1 18 (−17, 43) 42 (21, 57) 53 (12, 75) 64 (43, 78) 39 (26, 50) 43 (31, 53) .091
B/Yamagata 39 (−51, 75) 43 (−2, 69) 57 (0, 81) 66 (49, 78) 56 (41, 67) 57 (43, 68) .321
2011-2016
Overall 38 (29, 45) 36 (27, 43) 42 (33, 49) 47 (41, 53) 40 (37, 44) 41 (37, 44) .205
2013-2014 and 2015-2016 (same predominant A strain)
A/H1N1 38 (19, 53) 44 (30, 55) 40 (14, 58) 62 (51, 71) 48 (40, 54)  .025
Vaccination status × Site (ref., = Michigan) Pennsylvania 10 (−25, 36) .531
     Texas 19 (−24, 47) .338
     Washington 41 (15, 59) .005
2013-2014 and 2014-2015 (same predominant B lineage)
B/Yamagata −7 (−168, 57) 41 (−16, 70) 40 (0, 64) 52 (25, 70) 42 (23, 52) 41 (21, 56) .511
Note: Bold indicates significant vaccine effectiveness and significant interaction effect.
Regression models:
aBase case: logit(y) = β0 + β1*vaccination status + β2*age + β3*sex + β4*race/ethnicity + β5*any high-risk condition + β6*interval from onset to 
enrollment + β7*calendar time + error. 
bWith site added: logit(y) = β0 + β1*vaccination status + β2i*Clinical site + β3*age + β4*sex + β5*race/ethnicity + β6*any high-risk condition + β7*interval 
from onset to enrollment + β8*calendar time + error; i = site 1,2,3,4. 
cInteraction: logit(y) = β0 + β1*vaccination status + β2i*Clinical site + β3j*(vaccination status × Clinical site) + β4*age + β5*sex + β6*race/ethnicity + β7*any 
high-risk condition + β8*interval from onset to enrollment + β9*calendar time + error; i = site 1,2,3,4; j = 1,2,3,4 site*vaccination status. 
dMultivariable logistic regression models adjusted for age, sex, race/ethnicity, any high-risk condition, interval from onset to enrollment, and calendar 
time(bi-week). Race/ethnicity: Combined black, non-Hispanic, other race, non-Hispanic, and Hispanic any race into non-white. 
eP-value for interaction: (site × vaccination status). 
fSex is excluded from the adjusted model due to <5 in cell frequencies, and the validity of the model fit was questionable when included. 
gInsufficient data for analysis or convergence of the model. 
hSimilar data were originally published in Ref. [16] (Table S2), which included a 5th site, Wisconsin. 
388  |     BALASUBRAMANI et AL.
timing of the annual influenza epidemic varies with geographical 
location, that is, in the temperate Southern Hemisphere, the pri-
mary circulation period is May through October, whereas influ-
enza circulates all year in tropical areas.23 In large countries like 
Brazil23 or the USA,24 influenza peaks at different times in differ-
ent regions. However, studies from Japan25 and Saudi Arabia26 
have reported regional differences in incidence of influenza. 
In small countries especially those with similar geography like 
Norway, Sweden, and Denmark, similar seasonal epidemics have 
been reported. Spread of influenza was attributed to population 
size within these smaller countries when they were geographically 
similar, but not between those with differing geography.24 For ex-
ample, in the 2018-2019 season, Europe reported co-circulation 
of influenza A/H3N2 and A/H1N127 with varying proportions of 
these strains reported across countries. Comparing the spread 
of influenza across geographical regions has been recommended 
to increase understanding of the complex mechanisms of disease 
dynamics,24 and in turn, may contribute to better approaches to 
influenza prevention and mitigation.
Genetic sequencing of influenza viruses has the potential to 
increase our understanding of the causes of differential VE. In 
2014-15, most of the A/H3N2 viruses circulating in the USA were 
antigenically different from the A/H3N2 vaccine virus for that sea-
son, except in the Pennsylvania site where a mixture of A/H3N2 
clades occurred; correspondingly, only that site reported significant 
VE against A/H3N2 in 2014-15.15 Geographical differences among 
the sites might reflect the distribution of various mutations and con-
tribute to potential differences in vaccine effectiveness.
It is possible that differences in VE across sites are related to 
the types of vaccine used at any given site. During the time of 
this study, there were fewer options for vaccine types than are 
currently widely available; for example, cell-based vaccines, first 
available in 2016, represented only 10%-15% of the US market in 
2017-201828 and recombinant vaccines were licensed in 2017 after 
this study. In addition, during this time period, LAIV was recom-
mended, preferred, and not recommended.29 In the sites partici-
pating in this study, the use of trivalent standard-dose vaccine was 
declining, while quadrivalent standard-dose vaccine was increas-
ing, and high dose vaccine use was increasing despite its higher 
cost. The Washington site did not report any high dose vaccine 
among enrollees until 2015-2016, whereas other sites began to re-
port its use as early as 2013-2014.
Enrollees in this study of sites located hundreds to thousands 
of miles apart represent unique combinations of population densi-
ties, demographic characteristics, topography, modes of transpor-
tation, types of vaccines received, and perhaps vaccine coverage. 
Any or all of these factors might contribute to influenza epidemi-
ology and vaccine effectiveness. However, larger sample sizes may 
be necessary to elucidate those relationships. Further studies of 
differences in vaccine effectiveness by region may provide better 
estimates for computational modeling studies10 that are used to 
predict influenza epidemiology, burden, and anticipated resource 
needs.
4.1 | Strengths and limitations
Strengths of this study include using data from five influenza 
seasons with different circulating strains, inclusion of diverse 
geographical sites, and generally adequate sample size. The test-
negative design is subject to potential biases such as misclassifi-
cation of the exposure variable (vaccination status), confounding 
or effect modification by prior vaccination effects, and con-
founding by characteristics of study enrollees; indeed, our sites 
differed in demographic characteristics and vaccination rates. 
However, consistent protocols and rigorous attempts by the sites 
F I G U R E  2   Vaccine effectiveness by 
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to confirm vaccination status were employed to minimize bias. 
Insufficient numbers of circulating viruses in some sites in some 
seasons limited some VE estimates. Had all five US Flu VE net-
work sites participated, we may not have had low numbers for 
some analyses. It is possible that the differences observed may 
be attributed to unaccounted for differences among the Network 
sites. Vaccine type differed among sites and may affect overall 
VE. In addition, the effects of prior infection or prior seasons' 
vaccination are unknown.
5  | CONCLUSIONS
With few exceptions, site-specific vaccine effectiveness estimates 
aligned with each other and overall VE estimates. Observed VE dif-
ferences may reflect inherent differences in community characteris-
tics of the participating sites and highlight the importance of diverse 
settings for studying influenza vaccine effectiveness.
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